截至2025年一季报，共有26家机构持仓海泰新光，其中基金22家、其他3家、社保1家，合计持股数 5706.80万股，持股市值21.45亿元。 青岛海泰新光科技股份有限公司主营业务为医用内窥镜器械和光学产品的研发、生产、销售和服务。公 司主要产品分为高清荧光内窥镜器械、高清白光内窥镜器械、内窥镜器械配件、内窥镜器械维修等。公 司多年来在医用内窥镜器械领域和光学产品领域技术上不断开拓创新，在该领域实现了多项核心技术， 获得国内外发明专利37项，先后承担了多项国家及省市重点科技项目。 最新一期业绩显示，2025年一季报，公司实现营业收入1.47亿元，同比24.86%；净利润4668.87万元， 同比21.45%，销售毛利率64.98%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)69海泰新光29.2130.983.1241.94亿行业平均 46.4044.004.49100.23亿行业中值34.8137.612.2645.22亿1硕世生物-1850.69-1850.691.1437.05亿2天益医 疗-1581.08-2708.221.6920.15亿3澳华内镜-525.57263.604.2155. ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience a temporary pressure on performance in 2024, with a turning point anticipated in Q4 2024. The revenue for 2024 is projected to be 443 million yuan, a year-on-year decrease of 5.90%, while the net profit attributable to the parent company is expected to be 135 million yuan, down 7.11% year-on-year. In contrast, Q1 2025 shows a positive trend with revenue of 147 million yuan, a year-on-year increase of 24.86%, and a net profit of 47 million yuan, up 21.45% year-on-year [4][5][8]. Summary by Sections Financial Performance - In 2024, the company achieved revenue of 443 million yuan, a decrease of 5.90% year-on-year, and a net profit of 135 million yuan, down 7.11% year-on-year. The first quarter of 2025 saw revenue of 147 million yuan, reflecting a year-on-year increase of 24.86% [4][5][10]. Business Dynamics - The company's revenue in 2024 was impacted by inventory destocking from major clients, particularly in the medical endoscope segment, which generated 345 million yuan, a decrease of 7.04% year-on-year. However, Q4 2024 revenue rebounded to 124 million yuan, a year-on-year increase of 31.59%, indicating a recovery trend [5][6]. - The company has strengthened its collaboration with major clients, successfully passing various certifications for its U.S. subsidiary, which has facilitated order fulfillment. The establishment of production capabilities in Thailand has also enhanced its ability to meet U.S. demand [6]. Market Position and Growth Prospects - The company is making steady progress in its domestic complete machine business, with significant brand-building efforts leading to a notable increase in sales. The 4K camera system was successfully mass-produced in 2024, and a wide range of laparoscopes has been registered and launched in the domestic market [6]. - Revenue projections for 2025-2027 are 560 million yuan, 675 million yuan, and 817 million yuan, respectively, with growth rates of 26.5%, 20.5%, and 21.1%. The net profit for the same period is expected to be 188 million yuan, 232 million yuan, and 286 million yuan, with growth rates of 38.6%, 23.7%, and 23.1% [7][8].

Revenue and Profit - Company achieved total revenue of 147 million yuan in Q1 2025, representing a year-on-year growth of 24.86% [1] - Net profit attributable to shareholders was 46.69 million yuan, up 21.45% year-on-year [1] - Non-recurring net profit reached 46.26 million yuan, reflecting a growth of 26.89% year-on-year, indicating strong profitability during the reporting period [1] Profitability - Gross margin stood at 64.98%, an increase of 0.75 percentage points compared to the same period last year, indicating improved cost control [2] - Net margin was 31.17%, a decrease of 3.43 percentage points year-on-year, potentially due to increased period expenses [2] Expense Situation - Total sales, management, and financial expenses amounted to 21.51 million yuan, accounting for 14.64% of revenue, which is a 26.49% increase year-on-year [3] - The rapid growth of expenses is noteworthy and may impact future profit margins [3] Cash Flow and Asset Status - Operating cash flow per share was 0.53 yuan, reflecting a year-on-year increase of 63.03%, indicating healthy cash generation from operations [4] - Monetary funds reached 560 million yuan, up 29.54% year-on-year, showing a robust cash asset position [4] Accounts Receivable and Interest-Bearing Debt - As of the end of the reporting period, accounts receivable totaled 97.41 million yuan, a year-on-year increase of 17.19%, representing 71.97% of the latest annual net profit, highlighting a significant receivable volume that requires attention [5] - Interest-bearing debt surged from 2.21 million yuan to 82.27 million yuan, an increase of 3616.12%, which may exert pressure on the company's future debt repayment capacity [5] Dividends and Financing - Since its listing, the company has raised a total of 779 million yuan and distributed dividends totaling 207 million yuan, resulting in a dividend-to-financing ratio of 0.27 [6] - The company's performance is primarily driven by equity financing, necessitating further analysis of the long-term implications of this financing model [6] Summary - Overall, the company maintained steady performance growth in Q1 2025, but faces challenges in accounts receivable management and interest-bearing debt control [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's short-term revenue is impacted by order cycles, but its overseas expansion is progressing steadily [5] - The company reported a revenue of 443 million yuan for 2024, a year-on-year decrease of 5.90%, and a net profit attributable to the parent company of 135 million yuan, down 7.11% year-on-year [7] - The company expects revenue growth of 32.32% in 2025, reaching 586 million yuan, and a net profit of 187 million yuan, reflecting a growth rate of 37.84% [7] Financial Summary - Revenue projections for 2025-2027 are 586 million yuan, 738 million yuan, and 903 million yuan, with year-on-year growth rates of 32.32%, 25.99%, and 22.35% respectively [6][7] - The projected net profit for the same period is 187 million yuan, 238 million yuan, and 295 million yuan, with growth rates of 37.84%, 27.40%, and 24.32% respectively [6][7] - The company's earnings per share (EPS) are expected to be 1.55 yuan in 2025, 1.97 yuan in 2026, and 2.45 yuan in 2027 [6][7] - The price-to-earnings (P/E) ratios for 2025, 2026, and 2027 are projected to be 20.69, 16.24, and 13.06 respectively [6][7]

Investment Rating - The report maintains the investment rating for the company [1] Core Views - The company is projected to experience a revenue growth rate of 24.92% in 2025, followed by 23.72% in 2026 and 21.32% in 2027 [4] - The net profit attributable to the parent company is expected to increase by 32.02% in 2025, 24.84% in 2026, and 23.75% in 2027 [4] - The gross margin is forecasted to remain stable, with slight increases from 64.51% in 2024 to 65.70% in 2027 [4] - The company’s diluted EPS is projected to rise from 1.12 yuan in 2024 to 2.29 yuan in 2027 [4] Financial Summary Income Statement - Revenue is expected to grow from 442.83 million yuan in 2024 to 830.31 million yuan in 2027 [7] - Operating profit is projected to increase from 152.94 million yuan in 2024 to 315.49 million yuan in 2027 [7] - Net profit is forecasted to rise from 133.75 million yuan in 2024 to 276.06 million yuan in 2027 [7] Balance Sheet - Total assets are expected to grow from 1460.09 million yuan in 2024 to 1829.79 million yuan in 2027 [6] - Current assets are projected to increase from 851.29 million yuan in 2024 to 1224.82 million yuan in 2027 [6] - Total liabilities are expected to rise from 154.64 million yuan in 2024 to 227.11 million yuan in 2027 [6] Cash Flow Statement - Operating cash flow is projected to increase from 112.32 million yuan in 2024 to 276.82 million yuan in 2027 [6] - The net cash increase is expected to turn positive, from -68.41 million yuan in 2024 to 88.15 million yuan in 2027 [6]

Investment Rating - The report maintains the investment rating for the company [1] Core Views - The company is projected to experience a revenue growth rate of 24.92% in 2025, followed by 23.72% in 2026 and 21.32% in 2027 [4] - The net profit attributable to the parent company is expected to increase by 32.02% in 2025, 24.84% in 2026, and 23.75% in 2027 [4] - The gross margin is forecasted to remain stable, increasing slightly from 64.51% in 2024 to 65.70% in 2027 [4] - The company's diluted EPS is projected to rise from 1.12 yuan in 2024 to 2.29 yuan in 2027 [4] Financial Summary Income Statement - Revenue is expected to grow from 442.83 million yuan in 2024 to 830.31 million yuan in 2027 [7] - Operating profit is projected to increase from 152.94 million yuan in 2024 to 315.49 million yuan in 2027 [7] - Net profit is forecasted to rise from 133.75 million yuan in 2024 to 276.06 million yuan in 2027 [7] Balance Sheet - Total assets are expected to grow from 1460.09 million yuan in 2024 to 1829.79 million yuan in 2027 [6] - Current assets are projected to increase from 851.29 million yuan in 2024 to 1224.82 million yuan in 2027 [6] - Total liabilities are expected to rise from 154.64 million yuan in 2024 to 227.11 million yuan in 2027 [6] Cash Flow Statement - Operating cash flow is projected to increase significantly from 112.32 million yuan in 2024 to 276.82 million yuan in 2027 [6] - The net cash increase is expected to turn positive, rising from -68.41 million yuan in 2024 to 88.15 million yuan in 2027 [6]

报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2024年4月24日， 海泰新光 发布2024年年报及2025年一季报。 # 2024年拆分 医用内窥镜器械行业收入 3.45亿 元 （相比上年度下降7.04%）； 光学行业收入 0.95亿 元 （相比上年度下 降1.80%）。 另外，ODM业务收入2.81亿元，占比63.81%；OEM业务收入0.94亿元，占比21.39%；自主品牌产品收入 0.65亿元，占比14.80%。受国内医疗反腐因素影响，2024年公司自主品牌销售虽同比略有增长，但自主品 牌中整机产品销售同比增长2,276.71万元，同比增长显著。 (1)2024年，受美国客户去库存影响，公司前三季度海外营业收入下降明显。第四季度随着客户库存降到低 位，发货相比2023年同期大幅增长。延续客户需求增长趋势，公司海外业务收入会进一步增长； (2)2024年，公司国内整机业务推进良好，同比增长显著； # 财报数据 2024年公司实现收入 4.43亿 元，同比下降 5.90% ；实现归母净利润 1.35亿 元， 同比下降7.11%；实现扣 非归母净利润1.29亿元，同比下降 ...

青岛海泰新光科技股份有限公司 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 １ 号---规范运作》等相关规 定，青岛海泰新光科技股份有限公司（以下简称"公司"）董事会，就公司在任 独立董事王鸣、李勇、宋又强的独立性情况进行评估并出具如下专项意见： 经核查独立董事王鸣、李勇、宋又强任职经历以及签署的相关自查文件，上 迷人员未在公司担任除独立董事以外的任何职务,也未在公司主要股东公司担任 任何职务,与公司以及主要股东之间不存在利害关系或其他可能妨碍其进行独立 客观判断的关系。公司独立董事符合《上市公司独立董事管理办法》《上海证券 交易所科创板上市公司自律监管指引第1 号一规范运作》等规定中对独立董事独 立性的相关要求。 (以下元正文) 第四届董事会第四次会议文件 青岛海泰新光科技股份有限公司董事会 关于独立董事独立性自查情况的专项报告 青岛海泰新光科技 ...

证券代码：688677 证券简称：海泰新光 公告编号：2025-024 青岛海泰新光科技股份有限公司 关于提请股东大会授权董事会办理小额 快速融资相关事宜的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 青岛海泰新光科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第四届董事会第四次会议，审议通过了《关于提请股东大会授权董事会 办理小额快速融资相关事宜的议案》，具体情况如下： 2、发行方式、发行对象及向原股东配售的安排 本次发行股票采用向特定对象非公开发行的方式，发行对象为符合监管部 门规定的法人、自然人或者其他合法投资组织等不超过 35 名的特定对象。证券 投资基金管理公司、证券公司、合格境外机构投资者、人民币合格境外机构投 资者以其管理的两支以上产品认购的，视为一个发行对象。信托公司作为发行 对象的，只能以自有资金认购。最终发行对象将根据申购报价情况，由公司董 事会根据股东大会的授权与保荐机构（主承销商）协商确定。本次发行股票所 有发行对象均以现金方式认购。 3、定价基准日、定价原则、发行 ...

青岛海泰新光科技股份有限公司 第四届董事会第四次会议文件 青岛海泰新光科技股份有限公司 2024年度会计师事务所履职情况评估报告 青岛海泰新光科技股份有限公司（以下简称"公司"）聘请安永华明会计 师事务所（特殊普通合伙）（以下简称"安永华明"）作为公司2024年度财 务报告审计机构及内部控制审计机构。根据财政部、国务院国有资产监督管理 委员会、中国证券监督管理委员会颁布的《国有企业、上市公司选聘会计师事 务所管理办法》，公司对安永华明2024年度审计过程中的履职情况进行评估。 经评估，公司认为，安永华明在资质等方面合规有效，履职能够保持独立性， 勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 安永华明于1992年9月成立，2012年8月完成本土化转制，从一家中外合作的 有限责任制事务所转制为特殊普通合伙制事务所。安永华明总部设在北京，注 册地址为北京市东城区东长安街1号东方广场安永大楼17层01-12室。截至2024 年末拥有合伙人251人，首席合伙人为毛鞍宁先生。安永华明拥有财政部颁发 的会计师事务所执业资格，是中国首批获得证券期货相关业务资格和H股企业 审计资格事务所之一，在证券业务服务方面具有丰富 ...